Drugs / Hexavalent vaccine
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | Other | Shan 6 | — | — | “The pediatric hexavalent vaccine, Shan 6, was submitted in India in June.” sanofi.com ↗ |
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials · 1 met primary | ||||||
| Phase 3 | NCT03402776 | May 2018 → May 2020 | disease related to hematopoietic stem cell transplant | University Hospital, Grenoble | Unknown | No outcome recorded |
| Phase 3 | NCT01839175 | Apr 2013 → Jul 2014 | meningococcal infection, viral infectious disease | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT06748612 | Jan 2025 → Dec 2027 expected | poliomyelitis | International Centre for Diarrhoeal Disease Research, Bangladesh | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06879327 Background | May 2025 → Oct 2027 expected | Plasmodium falciparum malaria | PATH | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hexavalent Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06879327 ↗ |
| Known as | wP-Hexa | “Whole-cell pertussis hexavalent vaccine (wP-Hexa): Each 0.5 ml dose contains diphtheria toxoid, Tetanus toxoid, whole cell pertussis, Hepatitis B surface antigen, Haemophilus...” NCT06748612 ↗ |
| Modality | Vaccine | “DTaP-IPV-HB-PRP-T is a hexavalent vaccine” PMID 30471953 ↗ Nov 2018 |
| Route | Intramuscular | “0.5 mL intramuscular injection at 2, 3 and 4 months of age” NCT01839175 ↗ |